Sun, Dec 28, 2014, 3:14 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Aeterna Zentaris Inc. Message Board

mrbutters334 6 posts  |  Last Activity: Dec 2, 2014 11:41 AM Member since: Aug 7, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • According to Wall Street Journal
    Uptick/Downtick Trade Ratio
    Net Money Flow ($)
    Money flow gives a snapshot of relative buying and selling pressure in a stock. A ratio above one suggests greater buying pressure, below one suggests greater selling.

  • Reply to

    AEZS 2 drugs review by FDA, 130 P3 and 108 P2

    by strongbuy33 Oct 22, 2014 10:30 AM
    mrbutters334 mrbutters334 Oct 22, 2014 10:45 AM Flag

    strongbuy , this is at least 3 years old news. Do some better DD.

  • Clinical cancer research : an official journal of the American Association for Cancer Research 10/2014; DOI: 10.1158/1078-0432.CCR-14-0489
    Source: PubMed Phase I, Dose-Escalation Study of the Targeted Cytotoxic LHRH Analog AEZS-108 in Patients with Castration- and Taxane-Resistant Prostate Cancer.
    ABSTRACT Background: AEZS-108, formerly AN-152, is a cytotoxic hybrid molecule consisting of an LHRH agonist moiety covalently coupled to doxorubicin, allowing it to deliver doxorubicin selectively to cells expressing LHRH receptors. LHRH receptors are expressed on the cell membrane of many tumors, including prostate cancer (PC). This Phase I study determined the maximum tolerated dose (MTD) of AEZS-108 in men with taxane- and castration-resistant PC (CRPC) while providing additional information on the safety profile and efficacy of this agent. Materials and Methods: AEZS-108 was administered as an intravenous infusion every 21 days until progression or unacceptable toxicity in cohorts of 3 or 6 patients until the MTD was reached. Blood was collected for capture of circulating tumor cells (CTCs) to visualize internalization of AEZS-108, an auto-fluorescent molecule. Results: The MTD of AEZS-108 in this cohort was 210 mg/m2, which was lower than that seen in a Phase I study conducted in women with endometrial or ovarian cancers. The dose limiting toxicity was persistent neutropenia. Three patients had a PSA response with an additional 10 patients maintaining PSA stable disease. Of the 10 patients evaluable by RECIST criteria, 9 achieved stable disease. AEZS-108 internalization in CTCs was routinely visualized using its auto-fluorescence. Conclusion: These findings show that AEZS-108 has an acceptable safety profile and a signal of efficacy, lowering PSA in heavily pretreated patients with PC, and that internalization of AEZS-108 in PC CTCs may be a viable pharmacodynamic marker. A phase II study in men with PC is ongoing.

  • Since it tests for HGH (human growth hormone) orally and is not a blood test the NFL would be interested Macrilen for the purpose of finding concussions. Publicity like this would be enormous. Just think of all the college sports where concussions are rampant, football, soccer, rugby just to name a few. There could be hundreds of thousands of tests through out the world since AEZS has worldwide rights until 2027.
    Sources: NFL, Union Showing Renewed Interest In Negotiating HGH Testing Policy
    Published September 4, 2014
    The NFL and NFLPA are "showing renewed interest in attempting to implement changes to the sport’s drug policies that would include players being blood-tested" for HGH, according to sources cited by Mark Maske of the WASHINGTON POST. Sources on both sides said that there was an "increased willingness to try to find a way to overcome the remaining obstacles in the discussions and finish the long-awaited agreement."

  • Reply to


    by zlarssen Oct 10, 2014 10:40 AM
    mrbutters334 mrbutters334 Oct 11, 2014 2:16 PM Flag

    Blah blah blah. Live in the past dsco. How many id's do you have? Can't believe you just put all your energy into this one stock. You should put all your posts into a book it would be longer than War and Peace. Let's see where this stock is in the beginning of November. I say up .

  • Reply to


    by zlarssen Oct 10, 2014 10:40 AM
    mrbutters334 mrbutters334 Oct 11, 2014 10:28 AM Flag

    Actually raising cash after the Peri failure was a good move looking back. That was equal to raising cash at over 5 bucks a share now. With bio's how else are they going to raise money? You complain about bad management before so now they got more qualified people in the top positions and the company is moving forward you still complain.. The new management filed the NDA where old management was dragging it's feet. Egromed a professional company running the Aezs-108 phase 3 trial plus they are putting in 10 million for a single digit royalty. The recruitment has been good. Results 1st half of 2015. The Ascend deal should bring in a small amount of income look up the deal for details.. If Aezs-108 is positive that will be huge since it is a delivery system and can be used for other cancers the pps will soar. You still talk about Engle who has been gone for years, why is that? Some of us long time longs do see a big improvement with the way the company is run and I am glad to see someone making aggressive changes. The pps will rise as the FDA decision is in a few weeks. Since Macimorelin is a test with over 90% success rate and will be the only oral test for HGH there is a high chance of approval. If Aezs-108 is successful maybe Aezs could be the next Jazz.. The pps will rise with all the events coming up. This is the best position Aezs is at in a long time. Also the total amount Aezs can raise for selling stock is 15 million. There is also only 6.5 % of the float short which is small. Also look up the salaries for management. They are actually low compared to other bio's with less to offer than Aezs. Inquiring minds want to know your agenda dsco since you state you have no fi
    nancial l interest in Aezs.

0.5895+0.0025(+0.43%)Dec 26 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Virgin America Inc.
NASDAQFri, Dec 26, 2014 4:00 PM EST
Fluor Corporation
NYSEFri, Dec 26, 2014 4:03 PM EST